CT-P6 + Herceptin + Paclitaxel

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metastatic Breast Cancer

Conditions

Metastatic Breast Cancer

Trial Timeline

Jun 1, 2010 โ†’ Mar 1, 2015

About CT-P6 + Herceptin + Paclitaxel

CT-P6 + Herceptin + Paclitaxel is a phase 3 stage product being developed by Celltrion for Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01084876. Target conditions include Metastatic Breast Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT01084876Phase 3Completed
NCT01084863Phase 1/2Completed

Competing Products

20 competing products in Metastatic Breast Cancer

See all competitors